Peptipedia
Growth HormoneNot FDA ApprovedClinical Trials

GHRP-2

Also known as Growth Hormone Releasing Peptide 2, Pralmorelin, KP-102

A synthetic hexapeptide that acts on ghrelin receptors to stimulate GH release from the pituitary. Has the strongest GH-releasing effect among GHRPs.

Approved in some countries for GH deficiency diagnosis
CompareFind Vendors

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

100-300 mcg per injection

Frequency

2-3 times daily

Duration

8-12 weeks

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 100-300 mcg per injection via Subcutaneous injection, 2-3 times daily. Dose range: 100-300 mcg per dose. Duration: 8-12 weeks.

Timing & Administration

Administer via Subcutaneous injection. Frequency: 2-3 times daily.

Mechanism of Action

Acts on ghrelin receptors to stimulate GH release from the pituitary. Produces elevated cortisol and prolactin compared to alternatives like ipamorelin. Less appetite stimulation than GHRP-6.

Research Summary

Evidence level: clinical trials. Clinical status: Approved in some countries for GH deficiency diagnosis.

Side Effects & Safety

Important Warnings

  • Contraindicated with active malignancies
Increased appetite
water retention
fatigue
headache
nausea
cortisol/prolactin elevation
histamine release risk

References

No references available.

Related Peptides

Browse all →
IpamorelinGrowth Hormone

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin.

View profile
CJC-1295Growth Hormone

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary.

View profile
TesamorelinGrowth Hormone

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.

View profile